×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KALV – kalvista pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KALV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/18
07:00 am
kalv
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
Low
Report
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
2/17
09:36 am
kalv
Most shorted stocks with up to $2B market cap as of mid-February [Seeking Alpha]
Low
Report
Most shorted stocks with up to $2B market cap as of mid-February [Seeking Alpha]
2/12
07:16 am
kalv
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting [Yahoo! Finance]
Low
Report
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting [Yahoo! Finance]
2/12
07:00 am
kalv
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
Low
Report
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
2/11
03:46 pm
kalv
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion [Seeking Alpha]
Low
Report
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion [Seeking Alpha]
2/3
07:00 am
kalv
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/2
03:51 pm
kalv
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results [Yahoo! Finance]
Low
Report
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results [Yahoo! Finance]
1/24
05:09 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
04:30 pm
kalv
kalvista pharmaceuticals, inc.
BEAT
Report
5.3%
kalvista pharmaceuticals, inc.
9/11/2025
07:00 am
kalv
kalvista pharmaceuticals, inc.
MISS
Report
-9.4%
kalvista pharmaceuticals, inc.
3/12/2025
07:00 am
kalv
kalvista pharmaceuticals, inc.
MISS
Report
-2.0%
kalvista pharmaceuticals, inc.
3/12/2025
07:00 am
kalv
kalvista pharmaceuticals, inc.
MISS
Report
-2.0%
kalvista pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/19
07:45 pm
kalv
Form 4 KalVista Pharmaceuticals For: Feb 17 Filed by: Palleiko Benjamin L
Low
Report
Form 4 KalVista Pharmaceuticals For: Feb 17 Filed by: Palleiko Benjamin L
2/19
07:45 pm
kalv
Form 4 KalVista Pharmaceuticals For: Feb 17 Filed by: Audhya Paul K.
Low
Report
Form 4 KalVista Pharmaceuticals For: Feb 17 Filed by: Audhya Paul K.
2/19
07:44 pm
kalv
Form 4 KalVista Pharmaceuticals For: Feb 17 Filed by: Yea Christopher
Low
Report
Form 4 KalVista Pharmaceuticals For: Feb 17 Filed by: Yea Christopher
2/13
04:05 pm
kalv
Form 4 KalVista Pharmaceuticals For: Feb 11 Filed by: Palleiko Benjamin L
Low
Report
Form 4 KalVista Pharmaceuticals For: Feb 11 Filed by: Palleiko Benjamin L
1/26
05:01 pm
kalv
Form S-8 KalVista Pharmaceuticals
Low
Report
Form S-8 KalVista Pharmaceuticals
1/21
04:12 pm
kalv
Form 4 KalVista Pharmaceuticals For: Jan 16 Filed by: Arif Bilal
Medium
Report
Form 4 KalVista Pharmaceuticals For: Jan 16 Filed by: Arif Bilal
1/21
04:11 pm
kalv
Form 4 KalVista Pharmaceuticals For: Jan 16 Filed by: Sweeny Nicole
Medium
Report
Form 4 KalVista Pharmaceuticals For: Jan 16 Filed by: Sweeny Nicole
1/21
04:10 pm
kalv
Form 4 KalVista Pharmaceuticals For: Jan 16 Filed by: Audhya Paul K.
Medium
Report
Form 4 KalVista Pharmaceuticals For: Jan 16 Filed by: Audhya Paul K.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/9
Q1/2019 7/31/2019 EPS -0.420 ZacksConsensus -0.610 ActVsEst 0.190 - Beat
9.9%
3/23 Form SC 13G KalVista Pharmaceuticals Filed by: Ikarian Capital, LLC 8.8%
4/9 KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference 8.4%
12/7 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 6.6%
11/29 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.0%
7/19 Form 4 KalVista Pharmaceuticals For: Jul 17 Filed by: Cha Albert 4.4%
9/30 Form 4 KalVista Pharmaceuticals For: Sep 26 Filed by: SOLAND DANIEL B 4.3%
6/16 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
5/14 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%
10/25 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. 3.2%
3/23 Form SC 13G KalVista Pharmaceuticals Filed by: Ikarian Capital, LLC 8.8%
4/9 KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference 8.4%
12/7 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 6.6%
11/29 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.0%
7/19 Form 4 KalVista Pharmaceuticals For: Jul 17 Filed by: Cha Albert 4.4%
9/30 Form 4 KalVista Pharmaceuticals For: Sep 26 Filed by: SOLAND DANIEL B 4.3%
6/16 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
5/14 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%
10/25 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. 3.2%
TOP News Decliners
3/10
Form 10-Q KalVista Pharmaceuticals For: Jan 31
-14.8%
3/10 KalVista Pharmaceuticals Reports Fiscal Third Quarter Results -13.7%
4/30 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.7%
5/31 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.7%
12/26 Form 4 KalVista Pharmaceuticals For: Dec 20 Filed by: Crockett Thomas Andrew -6.8%
12/3 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. -6.8%
2/22 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.8%
7/1 Form 8-K KalVista Pharmaceuticals For: Jun 26 -4.5%
9/4 KalVista Pharmaceuticals: Our Verdict [Seeking Alpha] -4.3%
5/15 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its price target raised by analysts at Roth Capital from $25.00 to $30.00. They now have a "buy" rating on the stock. -4.2%
3/10 KalVista Pharmaceuticals Reports Fiscal Third Quarter Results -13.7%
4/30 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.7%
5/31 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.7%
12/26 Form 4 KalVista Pharmaceuticals For: Dec 20 Filed by: Crockett Thomas Andrew -6.8%
12/3 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. -6.8%
2/22 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.8%
7/1 Form 8-K KalVista Pharmaceuticals For: Jun 26 -4.5%
9/4 KalVista Pharmaceuticals: Our Verdict [Seeking Alpha] -4.3%
5/15 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its price target raised by analysts at Roth Capital from $25.00 to $30.00. They now have a "buy" rating on the stock. -4.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: